Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)

• Autors principals: Adam M. Bressler (Autor), Ali A. Hassoun (Autor), Louis D. Saravolatz (Autor), Valerie Ravenna (Autor), Chris N. Barnes (Autor), Bibiana Castaneda-Ruiz (Autor)
• Format: Llibre
• Publicat: Adis, Springer Healthcare, 2019-11-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Abstract Background Telavancin-a lipoglycopeptide antibacterial agent active against Gram-positive pathogens including methicillin-sensitive and -resistant Staphylococcus aureus (MRSA)-is approved in the USA for once-daily intravenous use. This registry study captured patient characteristics, prescr...